Myriad Genetics Acquisition of Counsyl, Inc.

05/29/2018
Forward Looking Statements

Some of the information presented here today may contain projections or other forward-looking statements regarding future events or the future financial performance of the Company. These statements are based on management’s current expectations and the actual events or results may differ materially and adversely from these expectations. We refer you to the documents the Company files from time to time with the Securities and Exchange Commission, specifically, the Company’s annual reports on Form 10-K, its quarterly reports on Form 10-Q, and its current reports on Form 8-K. These documents identify important risk factors that could cause the actual results to differ materially from those contained in the Company’s projections or forward-looking statements.
Myriad Genetics Acquisition of Counsyl, Inc.

Strategic Rationale

- Entry into high-growth reproductive testing market
- Comprehensive women’s health product offering
- Broad reimbursement coverage with potential for further expansion
- Potential for revenue synergies by tripling reproductive testing reach
- Potential for cost synergies throughout the enterprise

Consideration For Counsyl Shareholders

- Acquiring Counsyl for $375M consisting of cash and MYGN common stock
- Funding deal using cash on hand and existing revolving credit facility
- Expected to close in 1Q19

Myriad Financial Considerations

- Trailing twelve month revenue of $134M
- Will be neutral to adjusted EPS in FY19; >$0.20 accretive in FY20
- Counsyl will be incorporated into FY19 financial guidance provided on 4Q18 earnings call
- Expect attractive ROIC profile creating significant shareholder value
Strategic Rationale

Entry into high-growth reproductive testing market

Comprehensive women’s health product offering

Broad reimbursement with potential for future expansion

Potential for revenue synergies by tripling reproductive testing reach

Potential for cost synergies and expanded capabilities throughout the enterprise
Counsyl’s Portfolio of Women’s Health Products
*Allows Entry Into High-Growth Reproductive Testing Market*

- **Counsyl Foresight**
  - Expanded Carrier Screening
  - Clinical decision support for identifying inheritable disorders

- **Counsyl Prelude**
  - Non-Invasive Prenatal Screening
  - Clinical decision support for chromosome conditions

- **Counsyl Reliant**
  - Hereditary Cancer Testing
  - Clinical decision support for up to nine cancers
Snapshot of Counsyl
Rapidly Growing Diagnostic Business in Women’s Health Market

Revenue

Revenue (in mil.)

FY16A  $93
FY17A  $112
FY18E  $138

Revenue

- ForeSight ECS 64%
- Prelude NIPS 28%
- Reliant Hereditary Cancer 8%
Expanded Carrier Screening Market Opportunity

Multiple Opportunities for Growth

Large, Expanding Market For ECS

≈4.2 Million Pregnant Women

+ Pre-Conception Testing

+ Partner Testing

Limited Carrier Screening
≈500K tests

Expanded Carrier Screening
≈400K tests

No Carrier Screening
3.3M Tests

Conversion
From CF only or limited screens

Adoption
By physicians and medical societies

Positive
ACOG recognition of expanded carrier screening
NIPS Market Expansion
Advancing Towards Standard of Care for All Women

≈4.2M Pregnancies in the U.S. Annually

Emerging Adoption
in average-risk population as commercial payer coverage increases

Continued Expansion
in high-risk populations

NIPS Currently Performed
NIPS Market Opportunity

>3x

Average Risk
High Risk
Rapid Growth Expected in Reproductive Testing Market

60% Increase in U.S. Test Volume Over Next Five Years

U.S. Reproductive Testing Market

NIPS

<table>
<thead>
<tr>
<th>Year</th>
<th>Reproductive Testing Volume (in tests)</th>
</tr>
</thead>
<tbody>
<tr>
<td>FY15</td>
<td>500,000</td>
</tr>
<tr>
<td>FY18</td>
<td>1,000,000</td>
</tr>
<tr>
<td>FY23</td>
<td>2,000,000</td>
</tr>
</tbody>
</table>

Reproductive health market grows at low double-digit rate to 3.5M tests by FY23

Source: Counsyl, Public filings for SQNM, NTRA, and ILMN
Strategic Rationale

Entry into high-growth reproductive testing market

Comprehensive women’s health product offering

Broad reimbursement with potential for future expansion

Potential for revenue synergies by tripling reproductive testing reach

Potential for cost synergies and expanded capabilities throughout the enterprise
## Strong Strategic Fit Within 4 in 6 Strategy

**Announcing Formation of Women’s Health Business Unit**

<table>
<thead>
<tr>
<th>Risk?</th>
<th>Diagnosis?</th>
<th>Prognosis?</th>
<th>Therapy?</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>myriad. WOMEN’S HEALTH</strong></td>
<td><strong>myRisk®</strong></td>
<td><strong>Counselling Foresight</strong>&lt;br&gt;<strong>Counselling Prelude</strong></td>
<td><strong>genesight</strong></td>
</tr>
<tr>
<td><strong>myriad. ONCOLOGY</strong></td>
<td><strong>myRisk®</strong></td>
<td><strong>EndoPredict®</strong></td>
<td><strong>myChoice HRD</strong></td>
</tr>
<tr>
<td><strong>myriad. UROLOGY</strong></td>
<td><strong>myRisk®</strong></td>
<td><strong>Prolaris</strong></td>
<td></td>
</tr>
<tr>
<td><strong>myriad. DERMATOLOGY</strong></td>
<td><strong>myPath®</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>myriad. NEUROSCIENCE</strong></td>
<td><strong>myPath®</strong>&lt;br&gt;<strong>BIPOLAR</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>myriad. AUTOIMMUNE</strong></td>
<td></td>
<td></td>
<td><strong>Vectra DA</strong></td>
</tr>
</tbody>
</table>

* Future potential product
Comprehensive Women’s Health Product Offering

Best-in-Class Suite of Products Addressing >$5.0B U.S. Market

40,000 physicians

Prospective Parents
4.2M patients per year
$2.0B U.S. market opportunity

Pregnant Women
4.2M patients per year
$2.0B U.S. market opportunity

Adult Women
>10M women in the U.S.
$20B U.S. market opportunity

myriad® WOMEN’S HEALTH
Expanded Carrier Screening (ECS):
Testing for over 175 recessive genetic disorders in prospective parents to assess risk in future children

- Counsyl is the market leader with ≈20% market share
- Traditionally patients have been screened for cystic fibrosis, spinal muscular atrophy and fragile X but rapid growth is occurring in ECS
- ACOG updated guidelines in CY17 supporting ECS
- Highest detection rate of any test currently on the market
Non-Invasive Prenatal Screening:
Testing for trisomies, sex chromosome disorders and microdeletions in a developing fetus using maternal blood

- Prelude growth has significantly exceeded the market growth rate and currently has 8% market share
- Replaces serum-based markers and nuchal translucency with more accurate screening test
- ACOG professional guidelines could expand to provide greater access for average risk women
- Lowest cancellation rate of any test on the market
Strategic Rationale

- Entry into high-growth reproductive testing market
- Comprehensive women’s health product offering
- Broad reimbursement with potential for future expansion
- Potential for revenue synergies by tripling reproductive testing reach
- Potential for cost synergies and expanded capabilities throughout the enterprise
## Guideline Support For ECS and NIPS Increasing
### Driving Expanded Reimbursement Coverage

<table>
<thead>
<tr>
<th>Organization</th>
<th>Date</th>
<th>Statement</th>
</tr>
</thead>
<tbody>
<tr>
<td>ACOG</td>
<td>January 2015</td>
<td>Any patient may choose cell-free DNA (cfDNA) analysis as a screening strategy for common aneuploidies regardless of her risk status.</td>
</tr>
<tr>
<td>ASHG</td>
<td>March 2015</td>
<td>Comparably good results can be achieved in general obstetrical populations, making NIPT an alternative to current first-trimester screening protocols.</td>
</tr>
<tr>
<td>ISPD</td>
<td>April 2015</td>
<td>cfDNA screening as a primary test offered to all pregnant women currently is considered an appropriate protocol option.</td>
</tr>
<tr>
<td>ACOG</td>
<td>March 2016</td>
<td>All women should be offered the option of aneuploidy screening or diagnostic testing for fetal genetic disorder, regardless of maternal age.</td>
</tr>
<tr>
<td>ACOG</td>
<td>May 2016</td>
<td>The sensitivity and specificity in the general obstetric population are similar to the levels previously published for the high-risk population.</td>
</tr>
<tr>
<td>ACMG</td>
<td>July 2016</td>
<td>Inform all pregnant women that NIPS is the most sensitive screening option for traditionally screened aneuploidies (i.e. Patau, Edwards, and Down syndromes).</td>
</tr>
<tr>
<td>NSGC</td>
<td>October 2016</td>
<td>Supports prenatal cfDNA screening, also known as NIPT or NIPS, as an option for pregnant patients.</td>
</tr>
<tr>
<td>ACOG</td>
<td>April 2017</td>
<td>For scenarios in which different testing options are acceptable alternatives, obstetrician-gynecologists and other health care providers should determine which tests will be offered as the standard in their practices.</td>
</tr>
<tr>
<td></td>
<td>Foresight</td>
<td>Prelude</td>
</tr>
<tr>
<td>---</td>
<td>----------------------------</td>
<td>--------------------------</td>
</tr>
<tr>
<td></td>
<td>• Further guideline support for expanded carrier screening</td>
<td>• Further guideline support for average risk NIPS testing</td>
</tr>
<tr>
<td></td>
<td>• New ECS code at higher contracted ASP</td>
<td>• Average risk NIPS coverage expansion</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Medicaid coverage expansion</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Microdeletion coverage</td>
</tr>
</tbody>
</table>
Strategic Rationale

- Entry into high-growth reproductive testing market
- Comprehensive women’s health product offering
- Broad reimbursement with potential for future expansion
- Potential for revenue synergies by tripling reproductive testing reach
- Potential for cost synergies and expanded capabilities throughout the enterprise

1+1=3
Significant Opportunity for Revenue Synergies

Combined Sales Teams Will Triple Physician Reach in Women’s Health

- Largest genetics sales force in women’s health
- 3x physician reach for Counsyl’s tests
- Potential cross-selling opportunities in hereditary cancer
- 2x the size of the next largest competitor sales force
- 5% increase in market share = $50M in revenue and $25M in EBITDA
Strategic Rationale

- Entry into high-growth reproductive testing market
- Comprehensive women’s health product offering
- Broad reimbursement with potential for future expansion
- Potential for revenue synergies by tripling reproductive testing reach
- Potential for cost synergies and expanded capabilities throughout the enterprise
Potential for Cost Synergies Through the Enterprise

*Experienced Integration Team Managing Project*

- Same integration leadership with similar approach to the Assurex acquisition
- Leverage enterprise-wide functions such as R&D and Payer Markets
- Standardize informatics and IT platforms
- Leverage supplier purchasing power
- Combine commercial organizations
- Will look to combine the best functions and processes from both companies
Counsyl Software Tools Drive Ease of Use
Potential to Leverage Core Competency in Informatics

Workflow Solution for the Busy OB/GYN

Innovative Process, Price and Information Transparency for Physicians and Patients

- **PRE-TEST EDUCATION**
  - In-office education materials
  - Online learning

- **ORDERING**
  - EMR integration
  - Prior authorization

- **COVERAGE & ESTIMATES**
  - Transparent estimates
  - Real-time payer data
  - Self-pay options
  - No surprise bills

- **RESULTS DELIVERY**
  - Email and text notification
  - Clear & merged reports
  - Automated & tracked delivery

- **GENETIC COUNSELING**
  - On-demand
  - Coordination with physician
Myriad Genetics Acquisition of Counsyl, Inc.

**Strategic Rationale**

- Entry into high-growth reproductive testing market
- Comprehensive women’s health product offering
- Broad reimbursement coverage with potential for further expansion
- Potential for revenue synergies by tripling reproductive testing reach
- Potential for cost synergies throughout the enterprise

**Consideration For Counsyl Shareholders**

- Acquiring Counsyl for $375M consisting of cash and MYGN common stock
- Funding deal using cash on hand and existing revolving credit facility
- Expected to close in 1Q19

**Myriad Financial Considerations**

- Trailing twelve month revenue of $134M
- Will be neutral to adjusted EPS in FY19; >$0.20 accretive in FY20
- Counsyl will be incorporated into FY19 financial guidance provided on 4Q18 earnings call
- Expect attractive ROIC profile creating significant shareholder value

- Global leader in reproductive testing market
- Core products are Foresight™ expanded carrier screening test and Prelude™ non-invasive pre-natal screening test
- Calls on OBGYNs, reproductive endocrinologists, and maternal fetal medicine specialists
- Testing services provided from Counsyl’s CLIA laboratory in South San Francisco, CA